Title

Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases.

Document Type

Article

Publication Date

3-1-2016

Publication Title

Transplantation proceedings

Abstract

Inhibitors of mechanistic target of rapamycin are used in solid organ transplant procedures to avoid calcineurin inhibitor complications, including nephrotoxicity and malignancy. We present 2 cases of multivisceral transplantation for neuroendocrine tumor (NET) for which everolimus was implemented for its potential to prevent NET recurrence as well as preserve renal function. The first case was complicated by NET recurrence in the liver before initiation of everolimus. After initiation of everolimus, the patient developed a ventral hernia and elevated aminotransferase levels with nonspecific biopsy findings. The second case was complicated by cytomegalovirus infection with elevated everolimus trough levels as well as acute cellular rejection. Everolimus was reinitiated in both cases in addition to decreasing the dosage of tacrolimus, and there were no further complications. Everolimus was beneficial in stabilizing renal function in both patients and has the theoretical potential to prevent recurrence of NET.

Medical Subject Headings

Adult; Calcineurin Inhibitors; Everolimus; Female; Gastrointestinal Neoplasms; Graft Rejection; Humans; Immunosuppressive Agents; Intestines; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Tacrolimus

PubMed ID

27109983

Volume

48

Issue

2

First Page

485

Last Page

488

Share

COinS